Cardiology Online - International Academy of Cardiology
»search site
The International Academy of Cardiology is dedicated to the advancement of global research in cardiovascular medicine through the support of scientific meetings and publications.
   Home Page
   Discussion Groups
   Job Opportunities
   Contact Us





21st World Congress on Heart Disease



Tatiana A. Korolenko, Ph.D., Institute of Physiology and Basic Medicine, Novosibirsk, Russia


Objectives. The search of new serum non-lipid markers of atherosclerosis and predictors of cardiovascular events is important in contemporary society. The aim: to evaluate the activity of serum chitotriosidase (CHIT1) and compare it with inflammatory (hs-CRP) and common lipid markers in patients with atherosclerosis.

Background. Chitinases are enzymes effectors in both innate and acquired immunity. Recently enhanced expression and activity of CHIT1 in humans was suggested as a possible marker of atherosclerosis. In clinical proteomics, CHIT1 was included in the list of 177 biomarkers associated with the development of CVD.

Methods. 107 persons, male were enrolled: 1) group of low ischemic heart disease (IHD) risk, 25 donors (aged 31.46.5); 2) high IHD risk, 50 patients with hypertension, aged 56.82.9; 3) 32 patients with IHD (56.56,9) undergoing coronary bypass surgery (1 month, 1, 2 and 3 years after surgery, treated or non-treated by simvastatin, 20-40 mg/kg), Novosibirsk Regional Cardiovascular Unit. Patients with diabetes mellitus, kidney insufficiency were excluded from this study. Serum chitotriosidase activity was determined by fluorescent method against 4-methylumbelliferyl-beta-D-N-N-N-triacetylchitotrioside as a substrate (Guo et al., 1995).

Results. Serum CHIT1 activity (an enzyme released from the activated macrophages) was significantly increased in aged persons (p<0.01) as well as hs-CRP concentration (correlated with serum cholesterol and triglyceride levels). Baseline level of CHIT1 increased in patients of high risk of IHD (before operation, p<0.01 and 3-8 hrs after cardiosurgury, p<0.001). Simvastatin treatment (I month, 1, 2 and 3 years after cardiosurgery) significantly decreased serum CRP-hs, total cholesterol and non-HDL-cholesterol. However, simvastatin treatment of these patients had no effect on CHIT1 activity steady significantly increased at all periods studied (1, 2 and 3 years after surgery).

Conclusion. CHIT1 has been suggested to represent a new, independent non-lipid biomarker for the development of atherosclerosis.



©1998-2018 Cardiology Online, Inc. All rights reserved.
Cardiology Online is a registered trademark of Cardiology Online, Inc.